Antiangiogenic gene therapy of cancer: Recent developments

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Tandle, Anita ^a   Blazer III, Dan G ^a   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ARRESTEN; CANSTATIN; COMPLEMENTARY RNA; DOCETAXEL; ENDOSTATIN; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 18; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PROLACTIN; PROTEIN P53; RESTIN; SMALL INTERFERING RNA; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA; TUMSTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW TOXICITY; CANCER GENETICS; CAPILLARY LEAK SYNDROME; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; GENE THERAPY; GENE TRANSFER; GENETIC STABILITY; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTASIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RECTUM CANCER; REVIEW; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

EID: 4344625872     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-22     Document Type: Review

References (189)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10:255-261.
3. Ribatti D, Vacca A, Presta M: The discovery of angiogenic factors: a historical review. Gen Pharmacol 2000, 35:227-231.
4. Folkman J, Klagsbrun M: Angiogenic factors. Science 1987, 235:442-447.
5. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.
6. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997, 3:1222-1227.
7. Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997, 14:1495-1502.
8. Bertolini F, Mancuso P, Gobbi A, Pruneri G: The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol 2000, 28:993-1000.
9. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:149-153.
10. Breakthrough of the year. The runners-up Science 2003, 302:2039-2045.
11. Sedlacek HH: Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Crit Rev Oncol Hematol 2001, 37:169-215.
12. Vartanian RK, Weidner N: Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994, 144:1188-1194.
13. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407.
14. Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, Timpl R, Welsh M, Claesson-Welsh L: Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000, 95:3403-3411.
15. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284:808-812.
16. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
17. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
18. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13:159-167.
19. Gasparini G: Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 2001, 37:97-114.
20. Munshi NC, Wilson C: Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001, 28:565-569.
21. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002, 94:883-893.
22. Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G, Martinelli G, Bertolini F: Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003, 522:83-97.
23. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000, 97:14608-14613.
24. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 2001, 98:8018-8023.
25. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3:411-421.
26. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155:739-752.
27. Thies A, Mangold U, Moll I, Schumacher U: PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. J Pathol 2001, 195:537-542.
28. Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 1999, 91:359-367.
29. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
30. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001, 61:7669-7674.
31. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
32. Folkman J, Kalluri R: Cancer without disease. Nature 2004, 427:787.
33. Marx J: Angiogenesis. A boost for tumor starvation. Science 2003, 301:452-454.
34. Liau G, Su EJ, Dixon KD: Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches. Drug Discov Today 2001, 6:689-697.
35. Volpert OV, Alani RM: Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. Cancer Cell 2003, 3:199-200.
36. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG: Thrombospondins and tumor angiogenesis. Trends Mol Med 2001, 7:401-407.
37. Vailhe B, Feige JJ: Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Des 2003, 9:583-588.
38. Jin RJ, Kwak C, Lee SG, Lee CH, Soo CG, Park MS, Lee E, Lee SE: The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000, 7:1537-1542.
39. Liu P, Wang Y, Li YH, Yang C, Zhou YL, Li B, Lu SH, Yang RC, Cai YL, Tobelem G, Caen J, Han ZC: Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res 2003, 27:701-708.
40. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
41. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R: Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601.
42. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG: Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002, 277:27872-27879.
43. Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R, Sukhatme VP: Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002, 277:16464-16469.
44. Folkman J: Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003, 2:S127-33.
45. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002, 20:3792-3803.
46. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003, 21:223-231.
47. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, Libutti SK: Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000, 60:1503-1506.
48. Feldman AL, Alexander HR, Hewitt SM, Lorang D, Thiruvathukal CE, Turner EM, Libutti SK: Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst 2001, 93:1014-1020.
49. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003, 3:422-433.
50. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R: Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000, 275:21340-21348.
51. Maeshima Y, Colorado PC, Kalluri R: Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000, 275:23745-23750.
52. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, Kharbanda S, Kalluri R: Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001, 276:15240-15248.
53. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Ericksen MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R: Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000, 60:2520-2526.
54. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R: Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000, 275:1209-1215.
55. Xu R, Yao ZY, Xin L, Zhang Q, Li TP, Gan RB: NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Biochem Biophys Res Commun 2001, 289:264-268.
56. Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B, Sukhatme VP: Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999, 255:735-739.
57. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J: Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 1994, 59:471-482.
58. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
59. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996, 2:689-692.
60. Wahl ML, Moser TL, Pizzo SV: Angiostatin and Anti-angiogenic Therapy in Human Disease. Recent Prog Horm Res 2004, 59:73-104.
61. Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C, Zonnenberg BA, Schramel F, Gebbink MF, Voest EE: Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 2003, 9:4025-4033.
62. Lalani AS, Chang B, Lin J, Case SS, Luan B, Wu-Prior WW, VanRoey M, Jooss K: Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. Mol Ther 2004, 9:56-66.
63. Galaup A, Opolon P, Bouquet C, Li H, Opolon D, Bissery MC, Tursz T, Perricaudet M, Griscelli F: Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther 2003, 7:731-740.
64. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI: The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993, 133:1292-1299.
65. Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I: The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol 2003, 17:1815-1823.
66. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH: Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 2003, 63:386-393.
67. Bentzien F, Struman I, Martini JF, Martial J, Weiner R: Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 2001, 61:7356-7362.
68. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77-79.
69. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990, 82:848-853.
70. Kolber DL, Knisely TL, Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995, 87:304-309.
71. Belman N, Bonnem EM, Harvey HA, Lipton A: Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs 1996, 14:387-389.
72. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997, 3:437-442.
73. Li Y, Jin Y, Chen H, Jie G, Tobelem G, Caen JP, Han ZC: Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4. Cancer Biother Radiopharm 2003, 18:829-840.
74. Neville LF, Mathiak G, Bagasra O: The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997, 8:207-219.
75. Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, Alexander HR: Retroviral gene transfer of interferon- inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002, 99:149-153.
76. Jones PF: Not just angiogenesis - wider roles for the angiopoietins. J Pathol 2003, 201:515-527.
77. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 1998, 95:8829-8834.
78. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
79. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87:581-586.
80. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993, 178:1223-1230.
81. Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE: Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 1999, 5:3983-3989.
82. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000, 6:1678-1692.
83. Hurteau JA, Blessing JA, DeCesare SL, Creasman WT: Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2001, 82:7-10.
84. Mazzolini G, Prieto J, Melero I: Gene therapy of cancer with interleukin-12. Curr Pharm Des 2003, 9:1981-1991.
85. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996, 93:11302-11306.
86. Cao R, Farnebo J, Kurimoto M, Cao Y: Interleukin-18 acts as an angiogenesis and tumor suppressor. Faseb J 1999, 13:2195-2202.
87. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M: Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J Invest Dermatol 2002, 119:541-548.
88. Liu Y, Huang H, Saxena A, Xiang J: Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther 2002, 9:533-542.
89. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987, 47:5155-5161.
90. Dvorak HF, Gresser I: Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989, 81:497-502.
91. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995, 92:4562-4566.
92. Lindner DJ: Interferons as antiangiogenic agents. Curr Oncol Rep 2002, 4:510-514.
93. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, Bono M, Ferrantini M, Rozera C, Truini M, Belardelli F, Santi L, Noonan DM: Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol 2000, 156:1381-1393.
94. Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK: Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 2000, 60:70-80.
95. Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK: In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 1999, 59:205-212.
96. Gnant MF, Berger AC, Huang J, Puhlmann M, Wu PC, Merino MJ, Bartlett DL, Alexander H. R., Jr., Libutti SK: Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res 1999, 59:4668-4674.
97. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252.
98. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997, 14:2767-2774.
99. ten Hagen TL, Eggermont AM: Solid tumor therapy: manipulation of the vasculature with TNF. Technol Cancer Res Treat 2003, 2:195-203.
100. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N: TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004, 22:592-601.
101. Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP: Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 1998, 22:185-194.
102. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994, 8:171-176.
103. Holmgren L, Jackson G, Arbiser J: p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 1998, 17:819-824.
104. Su JD, Mayo LD, Donner DB, Durden DL: PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 2003, 63:3585-3592.
105. Szary J, Szala S: Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int J Cancer 2001, 91:835-839.
106. Oga M, Takenaga K, Sato Y, Nakajima H, Koshikawa N, Osato K, Sakiyama S: Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. Int J Oncol 2003, 23:73-79.
107. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999, 17:343-348.
108. Barron LG, Uyechi LS, Szoka F. C., Jr.: Cationic lipids are essential for gene delivery mediated by intravenous administration of lipoplexes. Gene Ther 1999, 6:1179-1183.
109. Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA: Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 2002, 87:106-112.
110. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN: Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997, 15:647-652.
111. Rodolfo M, Cato EM, Soldati S, Ceruti R, Asioli M, Scanziani E, Vezzoni P, Parmiani G, Sacco MG: Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther 2001, 8:491-496.
112. Chen QR, Kumar D, Stass SA, Mixson AJ: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999, 59:3308-3312.
113. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998, 101:1401-1413.
114. Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N: Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004, 108:301-306.
115. Janssen AP, Schiffelers RM, ten Hagen TL, Koning GA, Schraa AJ, Kok RJ, Storm G, Molema G: Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int J Pharm 2003, 254:55-58.
116. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M: Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003, 63:7400-7409.
117. Gu ZP, Wang YJ, Li JG, Zhou YA: VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. World J Gastroenterol 2002, 8:44-48.
118. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999, 59:895-900.
119. Marchand GS, Noiseux N, Tanguay JF, Sirois MG: Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. Am J Physiol Heart Circ Physiol 2002, 282:H194-204.
120. Shim WS, Teh M, Mack PO, Ge R: Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int J Cancer 2001, 94:6-15.
121. Dallabrida SM, De Sousa MA, Farrell DH: Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin. J Biol Chem 2000, 275:32281-32288.
122. Lipscomb EA, Dugan AS, Rabinovitz I, Mercurio AM: Use of RNA interference to inhibit integrin (alpha6beta4)-mediated invasion and migration of breast carcinoma cells. Clin Exp Metastasis 2003, 20:569-576.
123. Yang G, Cai KQ, Thompson-Lanza JA, Bast R. C., Jr., Liu J: Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression. J Biol Chem 2004, 279:4339-4345.
124. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
125. Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G: Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003, 303:1169-1178.
126. Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4:346-358.
127. Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM, Curiel DT: A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2000, 2:562-578.
128. Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner MK: Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002, 5:233-241.
129. Logg CR, Kasahara N: Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly efficient tumor transduction in vivo. Methods Mol Biol 2004, 246:499-525.
130. Rollins SA, Birks CW, Setter E, Squinto SP, Rother RP: Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Hum Gene Ther 1996, 7:619-626.
131. Ghazizadeh S, Carroll JM, Taichman LB: Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. J Virol 1997, 71:9163-9169.
132. Smith-Arica JR, Bartlett JS: Gene therapy: recombinant adeno-associated virus vectors. Curr Cardiol Rep 2001, 3:43-49.
133. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH: Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004, 109:513-519.
134. Giles J: Protests win reprieve for renowned medical lab. Nature 2003, 423:573.
135. Kay MA, Nakai H: Looking into the safety of AAV vectors. Nature 2003, 424:251.
136. Shichinohe T, Bochner BH, Mizutani K, Nishida M, Hegerich-Gilliam S, Naldini L, Kasahara N: Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther 2001, 8:879-889.
137. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM: Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A 2000, 97:12227-12232.
138. Latchman DS: Herpes simplex virus vectors for gene therapy. Mol Biotechnol 1994, 2:179-195.
139. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ: Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002, 76:791-801.
140. Khare PD, Liao S, Hirose Y, Kuroki M, Fujimura S, Yamauchi Y, Miyajima-Uchida H: Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene. Anticancer Res 2002, 22:2443-2446.
141. Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balyasnikova IV, Baker AH, Danilov SM, Curiel DT: Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001, 19:838-842.
142. Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S, Levkovitz H, Castel D, Goldberg I, Afek A, Kopolovitc Y, Harats D: Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 2001, 8:819-827.
143. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004, 10:415-427.
144. Tozer GM, Kanthou C, Parkins CS, Hill SA: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002, 83:21-38.
145. Pasqualini R, Koivunen E, Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997, 15:542-546.
146. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
147. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E: A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002, 8:751-755.
148. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R: Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999, 17:768-774.
149. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
150. Folkman J: Angiogenic zip code. Nat Biotechnol 1999, 17:749.
151. Masson-Gadais B, Houle F, Laferriere J, Huot J: Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 2003, 8:37-52.
152. Marshall JF, Hart IR: The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 1996, 7:129-138.
153. Eliceiri BP, Cheresh DA: The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999, 103:1227-1230.
154. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998, 4:408-414.
155. Thomas GJ, Lewis MP, Whawell SA, Russell A, Sheppard D, Hart IR, Speight PM, Marshall JF: Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol 2001, 117:67-73.
156. Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A: Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. Faseb J 1999, 13:727-734.
157. Poul MA, Marks JD: Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol 1999, 288:203-211.
158. Di Giovine M, Salone B, Martina Y, Amati V, Zambruno G, Cundari E, Failla CM, Saggio I: Binding properties, cell delivery, and gene transfer of adenoviral penton base displaying bacteriophage. Virology 2001, 282:102-112.
159. Burg MA, Jensen-Pergakes K, Gonzalez AM, Ravey P, Baird A, Larocca D: Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res 2002, 62:977-981.
160. Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
161. Vinogradov SV, Bronich TK, Kabanov AV: Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002, 54:135-147.
162. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
163. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ: Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 2000, 44:433-439.
164. Artemov D, Mori N, Okollie B, Bhujwalla ZM: MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003, 49:403-408.
165. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
166. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
167. Cavazzana-Calvo M, Thrasher A, Mavilio F: The future of gene therapy. Nature 2004, 427:779-781.
168. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002, 20:3906-3927.
169. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003, 63:8890-8898.
170. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
171. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE: Endostatin's Antiangiogenic Signaling Network. Mol Cell 2004, 13:649-663.
172. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003, 100:4766-4771.
173. Panka DJ, Mier JW: Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003, 278:37632-37636.
174. Xu R, Xin L, Fan Y, Meng HR, Li ZP, Gan RB: Mouse restin inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002, 34:138-142.
175. Corbacho AM, Martinez De La Escalera G, Clapp C: Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002, 173:219-238.
176. Bikfalvi A, Gimenez-Gallego G: The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost 2004, 30:137-144.
177. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
178. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999, 285:1926-1928.
179. Zhang M, Volpert O, Shi YH, Bouck N: Maspin is an angiogenesis inhibitor. Nat Med 2000, 6:196-199.
180. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
181. Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL, Li LY: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 1999, 82:131-136.
182. Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY: Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 2001, 89:1161-1167.
183. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.
184. Folkman J, Ingber DE: Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987, 206:374-383.
185. Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, Maurice DH, Bassuk JA: Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 2003, 278:37849-37857.
186. Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 2000, 19:569-580.
187. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA: Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000, 95:543-550.
188. Guo YL, Wang S, Colman RW: Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001, 21:1427-1433.
189. Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, Pang YP, McCrae KR: The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A 2002, 99:12224-12229